Published in J Clin Invest on July 01, 1975
The American Society for Clinical Investigation, 1952--1975: a personal perspective. J Clin Invest (2008) 0.78
On the origins of perceived unmanageability of large academic medical units. Trans Am Clin Climatol Assoc (1977) 0.75
Sustaining the spirit of inquiry: the key role of the department chairman. Presidential address delivered before the 75th annual meeting of the American Society for Clinical Investigation, Washington, DC, 1 May 1983. J Clin Invest (1983) 0.75
Presidential address: Mr. Hunter builds his dream department. Ann Surg (1984) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Aortic stenosis. Circulation (1968) 3.49
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Coronary-artery spasm. N Engl J Med (1978) 2.20
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med (1980) 2.20
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med (1980) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation (1971) 2.15
Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol (1965) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med (1980) 2.08
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA (2001) 2.07
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA (1996) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Modification of myocardial infarction size after coronary occlusion. Ann Intern Med (1973) 1.98
The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 1.97
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation (1998) 1.96
Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. N Engl J Med (1986) 1.96
Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N Engl J Med (1976) 1.92
Control of myocardial oxygen consumption: relative influence of contractile state and tension development. J Clin Invest (1968) 1.90
The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation (1987) 1.89
Rapid sequential visualization of the heart and great vessels in man using the wide-field anger scintillation camera. Radioisotope-angiography following the injection of technetium-99m. Circulation (1969) 1.86
Applying the open artery theory: use of predictive survival markers. Eur Heart J (1998) 1.85
Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med (1966) 1.83
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Cardiovascular control mechanisms in the conscious state. N Engl J Med (1975) 1.82
One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. Circulation (1992) 1.82
Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med (1994) 1.78
Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relations. Circulation (1977) 1.77
Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res (1967) 1.75
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J (2002) 1.73
Thirteenth Bowditch lecture. The determinants of myocardial oxygen consumption. Physiologist (1969) 1.70
Electrocardiographic diagnosis of myocardial infarction in the presence of complete left bundle branch block. Am Heart J (1988) 1.69
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med (1986) 1.69
Effects of exercise on myocardial force-velocity relations in intact unanesthetized man: relative roles of changes in heart rate, sympathetic activity, and ventricular dimensions. J Clin Invest (1965) 1.67
A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest (1968) 1.67
Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation (1980) 1.67
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol (1998) 1.67
Retracted Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci U S A (1981) 1.67
ACE inhibitors--a cornerstone of the treatment of heart failure. N Engl J Med (1991) 1.67
Contractile state of the left ventricle in man: instantaneous tension-velocity-length relations in patients with and without disease of the left ventricular myocardium. Circ Res (1968) 1.63
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 1.63
Mechanism of norepinephrine depletion in experimental heart failure produced by aortic constriction in the guinea pig. Circ Res (1965) 1.63
Comparison of long-term outcome after acute myocardial infarction in patients never graduated from high school with that in more educated patients. Multicenter Investigation of the Limitation of Infarct Size (MILIS). Am J Cardiol (1993) 1.63
Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. J Am Coll Cardiol (1990) 1.62